Oncomethylome Sciences achieves key milestone in Schering-Plough collaboration
OncoMethylome Sciences announced that it achieved a key milestone in its collaboration with Schering-Plough. Schering-Plough has approved OncoMethylome Sciences' sub contractor, BRT laboratories (Maryland, USA) as a clinical trial testing facility. The laboratory can now start to provide testing services for clinical trials that are an important component of the collaboration. This event triggers a milestone payment for OncoMethylome Sciences, who will also qualify to receive ongoing sample processing fees.
Starting immediately, the laboratory will be evaluating the methylation status of the MGMT gene in DNA extracted from brain tumor cells using OncoMethylome Sciences' patent-protected assay. Making this testing service available is a key milestone in OncoMethylome Sciences' collaboration with Schering-Plough. The tumor samples will originate from the multi-center brain cancer clinical trial conducted by the U.S.-based Radiation Therapy Oncology Group (RTOG), the European Organization for Research and Treatment of Cancer (EORTC), and supported by Schering-Plough.
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
